Novel antifungal from Viamet selected for NIH rare diseases drug program

Pharmaceutical company Viamet has been selected by the National Institutes of Health to develop one its drug compounds into a treatment for fungal infection cryptococcal meningitis, a fungal infection that affects the membranes covering the brain and spina... [more]

View complete MedCityNews article